Phenomenex, Inc. Release: New Immobilized Lux Chiral Columns Expand Selectivity And Solvent Robustness

Torrance, Calif. (September 13, 2016) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces Lux i-Cellulose-5 chiral columns, offering a new selectivity to the company’s high-quality LC/SFC media for chiral separations. This new Lux media is more robust than other chiral offerings on the market thanks to a manufactured chemical crosslinking between the polysaccharide and silica supports. This enables use of the i-Cellulose-5 columns with even the strongest organic solvents, and offers greater sample loading and method development flexibility. The dichlorophenylcarbamate selector of the new media combines well with Phenomenex’s other Lux chiral stationary phases to provide an even more comprehensive toolkit for chiral separations. Lux i-Cellulose-5 is an affordable alternative to other selectivities on the market, and is available in both 3µm and 5µm particle sizes to meet the needs of analytical and preparative applications.

“Our Lux polysaccharide chiral columns are known for their separation power, seamless scalability and reproducibility,” said Simon Lomas, strategic marketing manager for Phenomenex. “We are extremely excited to offer this versatile new chiral selectivity, along with its strong solvent robustness, to give customers greater chiral separation success rates and extended column lifetime.”

The Phenomenex Lux chiral column line of seven selectors comprises an affordable and complementary kit for chiral separations, featuring high efficiency, excellent loading capacity and pressure stability up to 300 bar in a wide range of conditions. Ideal applications for Lux columns include the separation of drug enantiomers from the pharmaceutical sector, chiral pesticides in agrochemical settings, and a range of other chiral-chemicals such as raw materials, intermediates and finished goods.

To complement its comprehensive Lux chiral column line, Phenomenex offers free chiral screening services with greater than 90 percent success rates from its PhenoLogix application development group, along with over 2,000 chiral applications online that are easily searchable by compound structure or name on www.phenomenex.com.

Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com or follow the company on Twitter @Phenomenex.

Back to news